Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipidemia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Restriction and Postprandial Lipemia

NCT05713370
View directory record Official record
Conditions
Sleep Deprivation, Obesity
Interventions
high fat meal
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Short-term Effects of Leptin in People With Lipodystrophy

NCT01778556
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

NCT01010841
View directory record Official record
Conditions
Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions
UltraMealPlus 360 (Medical food), Low-glycemic-load diet
Dietary Supplement · Other
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Jun 11, 2026, 3:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions
99mTc-tilmanocept SPECT/CT scanning
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

NCT00225589
View directory record Official record
Conditions
Hypercholesteremia
Interventions
Rosuvastatin calcium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 70 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
20
States / cities
Alhambra, California • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Replacing Energy From Solid Fats and Added Sugars (SoFAS) With Avocado

NCT04990817
View directory record Official record
Conditions
Elevated Triglycerides, Hypertriglyceridemia
Interventions
Average American Diet With SoFAS Replaced With Avocado, Average American Diet
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
21 Years to 74 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

NCT02622282
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Text Messages, Phone Calls, Handout
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jun 11, 2026, 3:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

NCT00927459
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PRO-040201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

NCT00753779
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jun 11, 2026, 3:53 AM EDT
Withdrawn No phase listed Observational

Genetic Influence on Statin Pharmacodynamics

NCT01569854
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Supplements, Placebo, or Rosuvastatin Study

NCT04846231
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional

A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia

NCT00945737
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Soy protein; 25 grams/day, Control protein
Dietary Supplement
Lead sponsor
Solae, LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Addison, Illinois • Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Jun 11, 2026, 3:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

NCT00006071
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

NCT00286481
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and simvastatin, Simvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
50
States / cities
Huntsville, Alabama • Chandler, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

NCT03973931
View directory record Official record
Conditions
Cardiovascular Diseases, Adherence, Medication, Medication Adherence, Diabetes Mellitus, Hypertension, Hyperlipidemias, Coronary Artery Disease, Atrial Fibrillation
Interventions
Nudge
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
9,501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

NCT00143676
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and atorvastatin, Atorvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
78
States / cities
Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Intensive Glycemic Control and Skeletal Health Study

NCT00324350
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
Interventions
hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 79 Years
Enrollment
7,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Minneapolis, Minnesota • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

NCT05552326
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
63
States / cities
Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 11, 2026, 3:53 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Butyrate Tablet BKR-017

NCT06556745
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
BKR-017
Drug
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

NCT00267254
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions
torcetrapib/atorvastatin, simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 11, 2026, 3:53 AM EDT
Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

NCT05852431
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
22 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 11, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT02265952
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jun 11, 2026, 3:53 AM EDT